Lu Dai

Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.

Federal Grant PI High Impact

Assistant Professor

UAMS

Also affiliated: Changchun University of Science and Technology (2025–2026); Liaoning University (2022–2024); Huaqiao University (2023); Beijing Institute of Technology (2023–2025); Roche (United States) (2021); Zhejiang Sci-Tech University (2022); The University of Texas MD Anderson Cancer Center (1993–1999); Zhejiang Normal University (2026); University of Kentucky (2014–2018); East China University of Science and Technology (2025); Medical University of South Carolina (2009); Sun Yat-sen University (2024); Guangxi Medical University (2016); China Three Gorges University (2024); Hangzhou Normal University (2017); Hohai University (2016); Zhejiang University of Science and Technology (2022); National University of Defense Technology (2000); Nanyang Technological University (2009–2013); Yangtze University (2023–2025); University of Bremen (2012); Genentech (2019–2023); Jilin University (2014–2026); Chinese Academy of Sciences (2025); Peking University (2009–2014); Fondazione Bruno Kessler (2012); Fudan University (2010); San Diego State University (1997–1998); Wenzhou Medical University (2023–2024); China Tobacco (2023); Southern University of Science and Technology (2024–2025); University Town of Shenzhen (2009–2012); Westlake University (2024); Kunming Children's Hospital (2022); Peking University Cancer Hospital (2024); Sun Yat-sen Memorial Hospital (2024); Zhongda Hospital Southeast University (2015–2017); Istituto Nazionale di Ricerca Metrologica (2012); Technical Institute of Physics and Chemistry (2025); Jiangsu Province Hospital (2025); Guangzhou Medical University Cancer Hospital (2015–2021); Guizhou Provincial People's Hospital (2023); Tumor Hospital of Guangxi Medical University (2016); Nanjing Jiangning Hospital (2026); Contemporary Amperex Technology Co., Limited. (2020); Nanjing First Hospital (2018–2023); Southwest Technology and Engineering Research Institute (China) (2022–2023); University of Houston (2021–2026); Hunan Agricultural University (2023); Southeast University (2015–2017); Nanjing Medical University (2018–2026); Guangzhou Medical University (2015–2021); University of California, Berkeley (2017–2025)

23 h-index 192 pubs 1,631 cited

Upstream record may be merged OpenAlex, the source of these figures, lists 54 institutions in 5 countries for this author record — a pattern that usually means it combines several researchers with similar names. The totals above may include work by other people.

Research Areas

Biomedical Subjects

Links

ORCID Lab Website Research Group

OverviewAI-generated summary

Lu Dai's research focuses on virus-associated malignancies, particularly those linked to Kaposi's sarcoma-associated herpesvirus (KSHV). Dai has received significant federal funding to investigate the role of macrophage migration inhibitory factor (MIF) in KSHV-associated malignancies, with a grant from the NIH/National Institute of Dental and Craniofacial Research totaling $306,000. Further funding from the NIH/National Institute of Allergy and Infectious Diseases ($229,500) supports the development of O’PROTACs-based degraders targeting oncogenic viral proteins. Another NIH/National Institute of Dental and Craniofacial Research grant ($152,000) targets IL1RAP in virus-associated malignancies.

With a publication record of 207 articles and an h-index of 24, Dai's work has been cited 1,726 times. Recent publications explore the implications of HIF-1α in pancreatic cancer tumorigenesis and progression, the role of miRNA 17 family in cisplatin-resistant non-small cell lung cancer (NSCLC), and the inhibition of hyaluronan-CD44 interactions in ovarian carcinoma cells and malignant peripheral nerve sheath tumors. Dai collaborates with researchers at the University of Arkansas for Medical Sciences, including Steven R. Post, Shengyu Mu, Lindsey Barrett, and Samantha Kendrick, with whom they have co-authored multiple publications.

Dai leads a research group and maintains an active lab website. Their scholarly output has led to recognition as a high-impact, highly cited researcher and a principal investigator on federal grants.

Metrics

h-index: 23
Publications: 192
Citations: 1,631

Positions

Assistant Professor publications 2026

University of Arkansas for Medical Sciences Institution web page

Selected Publications

Targeting BRD2 and BRD4 inhibit the growth of KSHV-infected immortalized endothelial cells through suppression of LANA translation (2026)

DOI OpenAlex
Recent Advances in Development of Kaposi's Sarcoma‐Associated Herpesvirus‐Latency‐Associated Nuclear Antigen Targeted Therapies (2025)

Journal of Medical Virology 3 citations DOI OpenAlex
Developing new ceramide analogs against non-small cell lung cancer (NSCLC) (2024)

American Journal of Cancer Research 3 citations DOI OpenAlex
Human endogenous retrovirus type K encoded Np9 oncoprotein induces DNA damage response (2024)

Journal of Medical Virology 9 citations DOI OpenAlex
Development of human endogenous retrovirus type K‐ related treatments for human diseases (2024)

Journal of Medical Virology 5 citations DOI OpenAlex
Role of lymphatic endothelium specific hyaluronan receptor 1 in virus infection and associated diseases (2024)

Journal of Medical Virology 3 citations DOI OpenAlex
Coinfections with additional oncoviruses in HPV+ individuals: Status, function and potential clinical implications (2024)

Journal of Medical Virology 7 citations DOI OpenAlex